SCHEMBL23085662

SCHEMBL23085662

COC[C@@H]1C[C@@H](NC(=O)c2nnc(-c3cc(C#N)ccc3OC)o2)CN1C(=O)OC(C)(C)C

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CTSS P25774 1/20 0.36
▸ CTSK P43235 1/20 0.36
▸ GPR119 Q8TDV5 3/20 0.36
▸ KDM4D Q6B0I6 1/20 0.35
▸ NSD2 O96028 1/20 0.35
▸ EGLN2 Q96KS0 1/20 0.35
▸ CETP P11597 1/20 0.35
▸ AR P10275 1/20 0.34
▸ UGCG Q16739 1/20 0.34
▸ GPR6 P46095 1/20 0.34
▸ TLR9 Q9NR96 1/20 0.34
▸ TLR8 Q9NR97 1/20 0.34
▸ TLR7 Q9NYK1 1/20 0.34
▸ LRRK2 Q5S007 1/20 0.34
▸ IRAK4 Q9NWZ3 1/20 0.34
▸ MALT1 Q9UDY8 1/20 0.33
▸ DRD2 P14416 1/20 0.33
▸ EGLN1 Q9GZT9 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29158599 1.00 CTSS (0.36) CTSSCTSKGPR119KDM4DNSD2
SCHEMBL29158603 1.00 CTSS (0.36) CTSSCTSKGPR119KDM4DNSD2
SCHEMBL30798694 1.00 CTSS (0.36) CTSSCTSKGPR119KDM4DNSD2
SCHEMBL29546545 0.91 CETP (0.35) GPR119EGLN2CETPARUGCG
SCHEMBL24370924 0.91 CETP (0.35) GPR119EGLN2CETPARUGCG
SCHEMBL23085845 0.90 LRRK2 (0.37) CTSSCTSKGPR119KDM4DNSD2
SCHEMBL29158564 0.90 LRRK2 (0.37) CTSSCTSKGPR119KDM4DNSD2
SCHEMBL29158567 0.90 LRRK2 (0.37) CTSSCTSKGPR119KDM4DNSD2
SCHEMBL29470224 0.90 LRRK2 (0.37) CTSSCTSKGPR119KDM4DNSD2
SCHEMBL23069404 0.90 LRRK2 (0.36) UGCGGPR6TLR9TLR8TLR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4025573-B9 SUBSTITUTED CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS MISSION THERAPEUTICS LTD (GB) 2024-11-20 — — EP disclosed
EP-4025573-B1 SUBSTITUTED CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS MISSION THERAPEUTICS LTD (GB) 2024-07-24 — — EP disclosed
US-20220315572-A1 SUBSTITUTED CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2022-10-06 — — US disclosed
EP-4025573-A1 SUBSTITUTED CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS Mission Therapeutics Limited (GB) 2022-07-13 — — EP disclosed
WO-2022084479-A1 N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2022-04-28 — — WO disclosed
WO-2021043870-A1 SUBSTITUTED CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS MISSION THERAPEUTICS LIMITED (GB) 2021-03-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220315572-A1 SUBSTITUTED CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS USP30, USP36, USP28 CTSS 1696/4885CTSK 2343/4885GPR119 4261/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback